TACIT THERAPEUTICS Trademark

Trademark Overview


On Tuesday, July 5, 2022, a trademark application was filed for TACIT THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the TACIT THERAPEUTICS trademark a serial number of 97489332. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, June 4, 2024. This trademark is owned by U1 Bio, Inc.. The TACIT THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

RNA editing gene therapeutics being pharmaceutical preparations for editing RNA for the treatment of inherited genetic diseases; RNA editing gene therapeutics being pharmaceutical preparations for editing RNA to treat inherited genetic diseases; RNA editing gene therapeutics being pharmaceutical preparations for editing RNA to treat inherited human genetic diseases; RNA-based gene therapies being pharmaceutical preparations for treatment of muscular dystrophies; RNA-based gene therapies being pharmaceutical preparations for the treatment of inherited neurological diseases; RNA-based gene therapies being pharmaceutical preparations for treatment of inherited retinal dystrophies; RNA-based gene therapies being pharmaceutical preparations for treatment of cancer; RNA-based gene therapies being pharmaceutical preparations for treatment of genetic liver diseases; RNA-based gene therapies being pharmaceutical preparations for treatment of inherited blood disorders
tacit therapeutics

General Information


Serial Number97489332
Word MarkTACIT THERAPEUTICS
Filing DateTuesday, July 5, 2022
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, June 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 4, 2024

Trademark Statements


Goods and ServicesRNA editing gene therapeutics being pharmaceutical preparations for editing RNA for the treatment of inherited genetic diseases; RNA editing gene therapeutics being pharmaceutical preparations for editing RNA to treat inherited genetic diseases; RNA editing gene therapeutics being pharmaceutical preparations for editing RNA to treat inherited human genetic diseases; RNA-based gene therapies being pharmaceutical preparations for treatment of muscular dystrophies; RNA-based gene therapies being pharmaceutical preparations for the treatment of inherited neurological diseases; RNA-based gene therapies being pharmaceutical preparations for treatment of inherited retinal dystrophies; RNA-based gene therapies being pharmaceutical preparations for treatment of cancer; RNA-based gene therapies being pharmaceutical preparations for treatment of genetic liver diseases; RNA-based gene therapies being pharmaceutical preparations for treatment of inherited blood disorders
NOT AVAILABLE"THERAPEUTICS"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 1, 0001
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTACIT THERAPEUTICS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSOUTH SAN FRANCISCO, CA 94080

Party NameTACIT THERAPEUTICS, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressSOUTH SAN FRANCISCO, CA 94080

Party NameU1 Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Friday, July 8, 2022NEW APPLICATION ENTERED
Friday, July 8, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 19, 2023ASSIGNED TO EXAMINER
Friday, April 21, 2023NON-FINAL ACTION WRITTEN
Friday, April 21, 2023NON-FINAL ACTION E-MAILED
Friday, April 21, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 9, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, August 9, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, August 9, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, September 20, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, September 22, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, September 22, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, September 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, September 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, September 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 26, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 26, 2023TEAS PETITION TO REVIVE RECEIVED
Tuesday, September 26, 2023PETITION TO REVIVE-GRANTED
Tuesday, September 26, 2023NOTICE OF REVIVAL - E-MAILED
Tuesday, September 26, 2023NOTICE OF REVIVAL - E-MAILED
Friday, February 16, 2024ASSIGNED TO LIE
Friday, February 16, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 16, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 2, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, May 2, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, May 2, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, May 2, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, May 2, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 15, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 4, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 4, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED